[Bacterial translocation in intestinal transplant]

Area of Science:

• Gastroenterology and Hepatology
• Surgical Innovation
• Infectious Disease Management

Background:

• Bacterial translocation is a significant complication following small bowel transplantation (SBT).
• Managing bacterial translocation is crucial for improving patient survival after SBT.
• The role of prophylactic antibiotics in mitigating post-SBT complications requires further investigation.

Purpose of the Study:

• To evaluate the impact of ceftriaxone on bacterial translocation.
• To assess the effect of ceftriaxone on survival rates after SBT in a large animal model.
• To determine if ceftriaxone influences the efficacy of immunosuppressive therapy in SBT.

Main Methods:

• A randomized controlled trial involving 21 pigs undergoing small bowel transplantation.
• Four groups were studied: SBT alone, SBT with immunosuppression, SBT with ceftriaxone, and SBT with both ceftriaxone and immunosuppression.
• Bacterial cultures of blood, spleen, liver, mesenteric lymph nodes, and ileal biopsies were performed on postoperative days 0, 3, and 7.

Main Results:

• Ceftriaxone administration reduced the incidence of positive bacterial cultures, particularly for enterobacteria, on postoperative days 3 and 7.
• Early mortality (before postoperative day 7) was 50% in the control groups (SBT alone or with immunosuppression) but 0% in groups receiving ceftriaxone.
• Immunosuppression did not significantly alter the outcomes related to bacterial translocation or mortality.

Conclusions:

• Ceftriaxone demonstrates a significant benefit in reducing bacterial translocation and early mortality following small bowel transplantation in pigs.
• Prophylactic use of ceftriaxone is a promising strategy to improve outcomes after SBT.
• Further research is warranted to translate these findings to clinical practice in human SBT recipients.